Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03706235 · ClinicalTrials.gov registry record

Colvera for Detection of Disease Recurrence

A clinical trial of Colorectal Adenocarcinoma, sponsored by Clinical Genomics Pathology.

Completed
Registry status
488
Enrollment target
12
Study locations

NCT03706235 is a study of Colorectal Adenocarcinoma that has completed, run by Clinical Genomics Pathology. The registered enrollment target is 488 participants, above the 293-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (67% higher). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03706235, a study of Colorectal Adenocarcinoma, has completed, sponsored by Clinical Genomics Pathology.

COMPLETED
Registry status
488 participants
Enrollment target
12
Study locations

Study Summary

To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.

Conditions Studied

Interventions

  • OTHER Blood draw (venipuncture)

Study Locations (12)

Illinois

  • Rush University Medical Center - Chicago
  • NorthShore Health System - Evanston

California

  • Torrance Memorial Physician Network - Redondo Beach

Delaware

  • Bayhealth - Dover

Indiana

  • Indiana University - Indianapolis

Louisiana

  • Colon and Rectal Surgery Associates - Metairie

Michigan

  • Providence Hospital-Ascension Health - Novi

Minnesota

  • Virginia Piper Cancer Institute-Allina Health - Minneapolis

New Jersey

  • Essex Oncology - Belleville

Trial Details

FieldValue
Enrollment Target 488 participants
Start Date 2018-02-01
Est. Completion 2020-04-29

Sponsor

Clinical Genomics Pathology

2 total trials

What the Registry Record Tells You About NCT03706235

The ClinicalTrials.gov registry entry for NCT03706235 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 293-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (67% higher). The listed sponsor is Clinical Genomics Pathology, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood draw (venipuncture) is the first listed.

NCT03706235 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Illinois, California, Delaware.

Frequently Asked Questions

What is clinical trial NCT03706235 about?

NCT03706235 is a clinical study titled "Colvera for Detection of Disease Recurrence". To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.

What is the current status of trial NCT03706235?

This trial is currently completed. The enrollment target is 488 participants. The study started on 2018-02-01. Estimated completion is 2020-04-29.

What conditions does trial NCT03706235 study?

This clinical trial studies the following conditions: Colorectal Adenocarcinoma.

What interventions are being tested in trial NCT03706235?

The interventions under investigation include: Blood draw (venipuncture) (OTHER).

Who is sponsoring clinical trial NCT03706235?

This trial is sponsored by Clinical Genomics Pathology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03706235 being conducted?

This trial has 12 study locations across California, Delaware, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.